Nephro Trial Files: Lower Dose PD vs. Intermittent HD in AKI, Semaglutide for CKD in T2DM, and Posoleucel for BK Viremia
nephrotrialfiles.substack.com
Lower Dosage Acute Peritoneal Dialysis versus Acute Intermittent Hemodialysis in Acute Kidney Injury Parapiboon W et al. CJASN (May 2024) Bottom Line: This multicenter randomized controlled trial compared the outcomes between acute lower dosage PD and intermittent HD in patients with AKI. The primary outcome was 28-day mortality rate and secondary outcomes included dialysis-free survival, kidney recovery, metabolic profile, and procedure-related complications. The study found no significant difference in 28-day mortality between the two groups. However, there were more frequent intradialytic hypotension in the intermittent HD group and more frequent hypokalemia in the PD group. The study suggests that acute PD may be a viable alternative to intermittent HD in patients with AKI.
Nephro Trial Files: Lower Dose PD vs. Intermittent HD in AKI, Semaglutide for CKD in T2DM, and Posoleucel for BK Viremia
Nephro Trial Files: Lower Dose PD vs…
Nephro Trial Files: Lower Dose PD vs. Intermittent HD in AKI, Semaglutide for CKD in T2DM, and Posoleucel for BK Viremia
Lower Dosage Acute Peritoneal Dialysis versus Acute Intermittent Hemodialysis in Acute Kidney Injury Parapiboon W et al. CJASN (May 2024) Bottom Line: This multicenter randomized controlled trial compared the outcomes between acute lower dosage PD and intermittent HD in patients with AKI. The primary outcome was 28-day mortality rate and secondary outcomes included dialysis-free survival, kidney recovery, metabolic profile, and procedure-related complications. The study found no significant difference in 28-day mortality between the two groups. However, there were more frequent intradialytic hypotension in the intermittent HD group and more frequent hypokalemia in the PD group. The study suggests that acute PD may be a viable alternative to intermittent HD in patients with AKI.